Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

被引：1
|
作者：
Gargiulo, Luigi [1 ,2 ]
Ibba, Luciano [1 ,2 ]
Bianco, Matteo [1 ,2 ]
Di Giulio, Sara [1 ,2 ]
Alfano, Alfano [1 ,2 ]
Ingurgio, Ruggero Cascio [1 ,2 ]
Facheris, Paola [1 ]
Perugini, Chiara [1 ]
Valenti, Mario [1 ,2 ]
Costanzo, Antonio [1 ,2 ]
Narcisi, Alessandra [1 ]
机构：
[1] IRCCS Humanitas Res Hosp, Dermatol Unit, Rozzano, Italy
[2] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Italy
来源：
JOURNAL OF DERMATOLOGICAL TREATMENT | 2024年 / 35卷 / 01期
关键词：
DOUBLE-BLIND; ADOLESCENTS; PLACEBO; ADULTS; SAFETY;
D O I：
10.1080/09546634.2024.2375102
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China
    Zhu, Jiling
    Wu, Hanwen
    Ye, Yahui
    Xu, Qiuyang
    Shao, Junyi
    Bai, Zicheng
    Zhou, Yiwen
    Li, Zhenyan
    Liu, Jingjing
    Li, Zhiming
    DERMATITIS, 2024, 35 (06) : 636 - 645
  • [32] Dupilumab prevents flares in adults with moderate-to-severe atopic dermatitis in a 52-week, randomized, controlled, phase 3 trial
    Merola, J. F.
    Sidbury, R.
    Wollenberg, A.
    Chen, Z.
    Zhang, A.
    Shumel, B.
    Rossi, A. B.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2020, 140 (07) : S53 - S53
  • [33] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Paller, Amy S.
    Flohr, Carsten
    Eichenfield, Lawrence F. F.
    Irvine, Alan D. D.
    Weisman, Jamie
    Soung, Jennifer
    Correia, Ana Pinto
    Natalie, Chitra R. R.
    Capriles, Claudia Rodriguez
    Pierce, Evangeline
    Reifeis, Sarah
    Lima, Renata Gontijo
    Tubau, Clara Armengol
    Laquer, Vivian
    Weidinger, Stephan
    DERMATOLOGY AND THERAPY, 2023, 13 (07) : 1517 - 1534
  • [34] Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study
    Amy S. Paller
    Carsten Flohr
    Lawrence F. Eichenfield
    Alan D. Irvine
    Jamie Weisman
    Jennifer Soung
    Ana Pinto Correia
    Chitra R. Natalie
    Claudia Rodriguez Capriles
    Evangeline Pierce
    Sarah Reifeis
    Renata Gontijo Lima
    Clara Armengol Tubau
    Vivian Laquer
    Stephan Weidinger
    Dermatology and Therapy, 2023, 13 (7) : 1517 - 1534
  • [35] Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study
    Yang, Chin-Yi
    Lai, Po-Ju
    Chen, Chun-Bing
    Chan, Tom C.
    Hui, Rosaline Chung-Yee
    Huang, Yu-Huei
    Tseng, Han-Chi
    Lin, Shang-Hung
    Lu, Chun-Wei
    Lee, Hua-En
    Lin, Jing-Yi
    Chi, Min-Hui
    Tsai, Ming-Feng
    Hwang, Yih-Shiou
    Wang, Chuang-Wei
    Chu, Chia-Yu
    Chung, Wen-Hung
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
  • [36] Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study
    Andrea Chiricozzi
    Niccolò Gori
    Alessandra Narcisi
    Anna Balato
    Alessio Gambardella
    Michela Ortoncelli
    Angelo Valerio Marzano
    Riccardo Balestri
    Giovanni Palazzo
    Michele Pellegrino
    Marco Romanelli
    Giovanni Tripepi
    Ketty Peris
    Antonio Costanzo
    Drugs in R&D, 2022, 22 : 245 - 252
  • [37] Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study
    Chiricozzi, Andrea
    Gori, Niccolo
    Narcisi, Alessandra
    Balato, Anna
    Gambardella, Alessio
    Ortoncelli, Michela
    Marzano, Angelo Valerio
    Balestri, Riccardo
    Palazzo, Giovanni
    Pellegrino, Michele
    Romanelli, Marco
    Tripepi, Giovanni
    Peris, Ketty
    Costanzo, Antonio
    DRUGS IN R&D, 2022, 22 (03) : 245 - 252
  • [38] Early Achievement of High Treatment Targets in Moderate-to-Severe Atopic Dermatitis with Upadacitinib: Real-World Evidence from the Observational UP-TAINED Study
    Weidinger, Stephan
    Schadeck, Tobias
    Jacobs, Felix
    Weyergraf, Ansgar
    Mortazawi, Dariusch
    Hagemann, Tobias
    Abousamra, Fatima
    Mosch, Thomas
    Fritz, Bjoern
    Lauffer, Felix
    DERMATOLOGY AND THERAPY, 2025, : 919 - 931
  • [39] Correspondence on "Efficacy, Safety, and Early Relapse after Cessation of Upadacitinib Versus Dupilumab in Adolescents With Moderate-to-Severe Atopic Dermatitis: A Real-World Study in China"
    Shi, Xiaojun
    Fan, Kaiqi
    Lin, Zhimin
    Li, Chen
    DERMATITIS, 2025,
  • [40] Real-world effectiveness and safety of dupilumab in managing children and adolescents with moderate-to-severe atopic dermatitis
    Marshall, Claire
    Littlewood, Zoe
    Herety, Nichola
    Heal, Calvin
    Sharif, Jennifer
    Clayton, Tim
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 196 - 196
12345